文献速递血脂与心血管预防

美国成人家族性高胆固醇血症或其他严重血脂异常者的胆固醇筛查、知晓率及他汀治疗率(1999-2014)

Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014).
PubMed 文献 · Circulation · 2018-03-26

该研究基于1999至2014年美国国家健康与营养调查(NHANES)数据,估计美国成人中家族性高胆固醇血症(FH)及严重血脂异常者的筛查、知晓和他汀治疗率。结果显示,FH或严重血脂异常成人胆固醇筛查和知晓率较高(>80%),但FH者他汀使用率仅52.3%,严重血脂异常者仅37.6%,且FH者中仅30.3%使用高强度他汀。年轻和未参保患者筛查不足和治疗不足的风险最高。

要点

  • FH或严重血脂异常成人胆固醇筛查和知晓率超过80%,但治疗率低。
  • 确诊/可能FH成人他汀使用率52.3%,严重血脂异常者37.6%。
  • 仅30.3%使用他汀的FH患者接受高强度他汀治疗。

核心结论

  • 尽管胆固醇筛查和知晓率高,但仅约50%的FH成人接受他汀治疗,且高强度他汀使用更少;年轻和未参保患者筛查不足和治疗不足风险最高。

主要发现

  • 美国确诊/可能FH的估计患病率为0.47%(标准误0.03%),严重血脂异常患病率为6.6%(标准误0.2%)。
  • 确诊/可能FH或严重血脂异常成人中胆固醇筛查和知晓频率高(>80%)。
  • 确诊/可能FH成人他汀使用率为52.3%(标准误8.2%),严重血脂异常成人为37.6%(标准误1.2%)。
  • 确诊/可能FH患者中仅30.3%使用高强度他汀。
  • 严重血脂异常成人他汀使用率随时间从29.4%增至47.7%,但未快于一般人群趋势(从5.7%增至17.6%)。

临床怎么用

  • 应提高FH和严重血脂异常患者他汀处方率,尤其是高强度他汀的使用。
  • 年轻和未参保患者是筛查不足和治疗不足的高风险人群,需针对性改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial hypercholesterolemia (FH) and other extreme elevations in low-density lipoprotein cholesterol significantly increase the risk of atherosclerotic cardiovascular disease; however, recent data suggest that prescription rates for statins remain low in these patients. National rates of screening, awareness, and treatment with statins among individuals with FH or severe dyslipidemia are unknown. METHODS: Data from the 1999 to 2014 National Health and Nutrition Examination Survey were used to estimate prevalence rates of self-reported screening, awareness, and statin therapy among US adults (n=42 471 weighted to represent 212 million US adults) with FH (defined using the Dutch Lipid Clinic criteria) and with severe dyslipidemia (defined as low-density lipoprotein cholesterol levels ≥190 mg/dL). Logistic regression was used to identify sociodemographic and clinical correlates of hypercholesterolemia awareness and statin therapy. RESULTS: The estimated US prevalence of definite/probable FH was 0.47% (standard error, 0.03%) and of severe dyslipidemia was 6.6% (standard error, 0.2%). The frequency of cholesterol screening and awareness was high (>80%) among adults with definite/probable FH or severe dyslipidemia; however, statin use was uniformly low (52.3% [standard error, 8.2%] of adults with definite/probable FH and 37.6% [standard error, 1.2%] of adults with severe dyslipidemia). Only 30.3% of patients with definite/probable FH on statins were taking a high-intensity statin. The prevalence of statin use in adults with severe dyslipidemia increased over time (from 29.4% to 47.7%) but not faster than trends in the general population (from 5.7% to 17.6%). Older age, health insurance status, having a usual source of care, diabetes mellitus, hypertension, and having a personal history of early atherosclerotic cardiovascular disease were associated with higher statin use. CONCLUSIONS: Despite the high prevalence of cholesterol screening and awareness, only ≈50% of adults with FH are on statin therapy, with even fewer prescribed a high-intensity statin; young and uninsured patients are at the highest risk for lack of screening and for undertreatment. This study highlights an imperative to improve the frequency of cholesterol screening and statin prescription rates to better identify and treat this high-risk population. Additional studies are needed to better understand how to close these gaps in screening and treatment.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bucholz EM, Rodday AM, Kolor K, et al. Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014). Circulation. 2018. PMID: 29581125. doi:10.1161/CIRCULATIONAHA.117.032321

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。